Homepage>Company>Media>Pharma News>2018>U.S. FDA has approved VIZIMPRO® (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer
U.S. FDA has approved VIZIMPRO® (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer